Subscribe To Our Free Newsletter |
GSK intends to sell its remaining stake in Haleon
GSK, which initially retained a near 13% stake in Haleon, had over the course of a year lowered its stake to 4.2%. Last year, GSK had said that the Haleon spin-off and subsequent stake sales would allow the company to sharpen its focus on vaccines and infectious diseases and fund deals to bolster a lacklustre drug pipeline.